Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K.

R. H. Ben-Joseph, David Brendan Price, Q. Zhang

Research output: Contribution to journalArticlepeer-review

28 Citations (Scopus)


The aim of this study was to assess changes in the costs of asthma drug therapy before and during the use of chronic montelukast treatment in the U.K. A retrospective cohort analysis of a primary care database in the U.K. was carried out. Patients with chronic montelukast use (greater than or equal to 140 once-daily doses) were selected for analysis. Benchmarking data were obtained for matched patients with chronic inhaled corticosteroid (ICS) use and patients with chronic salmeterol therapy with concomitant ICS use. The main outcome measures were changes in utilization and monthly cost of asthma therapies costs. Asthma patients experienced significant (P < 0.05) reductions in the monthly costs of ICS, short-acting P-agonists and antibiotics following chronic montelukast therapy. Monthly concomitant drug costs were reduced by pound7.49 per month, which offset 27.5% of the additional cost of montelukast, yielding an increase in total drug costs of pound 19.78 per month. Meanwhile, increased total drug costs for matched patients with chronic ICS use, and matched patients with chronic salmeterol therapy and concomitant ICS use, increased by pound5.37 per month and pound 44.55 per month respectively. Additionally, patients using chronic montelukast therapy experienced a statistically significant (P < 0.05) reduction in the use of short acting P-agonists, and antibiotics, suggesting improvement in asthma control.

Chronic use of montelukast therapy is associated with a reduction of concomitant drug therapy costs.

Original languageEnglish
Pages (from-to)83-89
Number of pages6
JournalRespiratory Medicine
Issue number1
Publication statusPublished - 2001


  • montelukast
  • asthma
  • cost
  • salmeterol
  • UK


Dive into the research topics of 'Changes in asthma drug therapy costs for patients receiving chronic montelukast therapy in the U.K.'. Together they form a unique fingerprint.

Cite this